THE MOLECULAR INTERACTION PATTERN OF LENVATINIB ENABLES INHIBITION OF WILD-TYPE OR KINASE-MUTATED FGFR2-DRIVEN CHOLANGIOCARCINOMA Article Swipe
Related Concepts
Lenvatinib
Tyrosine-kinase inhibitor
Tyrosine kinase
Acquired resistance
Cancer research
Medicine
Fibroblast growth factor receptor
Internal medicine
Receptor
Cancer
Sorafenib
Fibroblast growth factor
Hepatocellular carcinoma
Stephan Spahn
,
Fabian Kleinhenz
,
Aaron Stahl
,
Ekaterina Shevchenko
,
Yvonne Rasen
,
Christine Geisler
,
Kristina Ruhm
,
Marion Klaumuenzer
,
Holly Sundberg Malek
,
Khac Cuong Bui
,
Marius Horger
,
Saskia Biskup
,
Klaus Schulze‐Osthoff
,
Markus F. Templin
,
Nisar P. Malek
,
Antti Poso
,
Michael Bitzer
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.7456830
· OA: W4320859488
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.7456830
· OA: W4320859488
Enclosed are the molecular dynamics simulations of drug–FGFR2 systems and the MM-GBSA raw data. The zip archives include the molecular dynamics trajectory files in Desmond Maestro format (*_trj; *-out.cms), the naming of zip archives is as following: Drug_Studied FGFR2 mutant. MM-GBSA raw data is attached in the csv format.
Related Topics
Finding more related topics…